CSL plans flu vaccine BLA by 2007
This article was originally published in Pharmaceutical Approvals Monthly
CSL plans to submit a BLA "within 12 months for both multi-dose vial and thimerosal-free single-dose" formulations of an influenza vaccine, the Australian firm announces Feb. 7. A clinical study is slated to begin "later this year." An early 2007 submission could put the CSL flu vaccine on the U.S. market in time for the 2007-2008 season; the firm plans to supply "up to 20 mil. doses to the U.S. as the expanded plant comes online in 2008," CSL says. The company has manufactured flu vaccine in its Melbourne facility since 1968...
You may also be interested in...
Two top officials in the US FDA’s device center are warning of delays in the agency’s review of submissions for new products that aren’t directly tied to the coronavirus pandemic.
With 12 new BTDs announced so far this year, 2021 is on pace to match the COVID-19-depressed total number of designations in 2020. Here’s a breakdown of the candidates that have received the designation.
Popular expedited review program results in a higher approval rate than the related fast track designation, but the COVID-19 era is seeing a drop in designations and a rise in complete response letters for BTD programs.